Measles Antibody Levels in Young Infants.


Journal

Pediatrics
ISSN: 1098-4275
Titre abrégé: Pediatrics
Pays: United States
ID NLM: 0376422

Informations de publication

Date de publication:
12 2019
Historique:
accepted: 20 09 2019
pubmed: 23 11 2019
medline: 27 2 2020
entrez: 23 11 2019
Statut: ppublish

Résumé

Infants are often assumed to be immune to measles through maternal antibodies transferred during pregnancy and, in many countries, receive their first measles-containing vaccine at 12 to 15 months. Immunity may wane before this time in measles-eliminated settings, placing infants at risk for measles and complications. We investigated humoral immunity to measles in infants <12 months of age in Ontario, Canada. We selected sera collected at a tertiary pediatric hospital from infants <12 months who were born at ≥37 weeks' gestational age. We excluded infants with conditions that affect antibody levels. We selected ≤25 sera from 8 predetermined age bands and tested them for measles-neutralizing antibody using the plaque-reduction neutralization test. We calculated the proportion immune at each age band, and predictors of infant susceptibility were assessed by using multivariable logistic regression and Poisson regression. Of 196 infant sera, 56% (110 of 196) were from boys, and 35% (69 of 196) were from infants with underlying medical conditions. In the first month, 20% (5 of 25) of infants had antibodies below the protective threshold, which increased to 92% (22 of 24) by 3 months. By 6 months, all infants had titers below the protective threshold. In a multivariable analysis, infant age was the strongest predictor of susceptibility (odds ratio = 2.13 for each additional month increase; 95% confidence interval: 1.52-2.97). Most infants were susceptible to measles by 3 months of age in this elimination setting. Our findings inform important policy discussions relating to the timing of the first dose of measles-containing vaccine and infant postexposure prophylaxis recommendations.

Sections du résumé

BACKGROUND
Infants are often assumed to be immune to measles through maternal antibodies transferred during pregnancy and, in many countries, receive their first measles-containing vaccine at 12 to 15 months. Immunity may wane before this time in measles-eliminated settings, placing infants at risk for measles and complications. We investigated humoral immunity to measles in infants <12 months of age in Ontario, Canada.
METHODS
We selected sera collected at a tertiary pediatric hospital from infants <12 months who were born at ≥37 weeks' gestational age. We excluded infants with conditions that affect antibody levels. We selected ≤25 sera from 8 predetermined age bands and tested them for measles-neutralizing antibody using the plaque-reduction neutralization test. We calculated the proportion immune at each age band, and predictors of infant susceptibility were assessed by using multivariable logistic regression and Poisson regression.
RESULTS
Of 196 infant sera, 56% (110 of 196) were from boys, and 35% (69 of 196) were from infants with underlying medical conditions. In the first month, 20% (5 of 25) of infants had antibodies below the protective threshold, which increased to 92% (22 of 24) by 3 months. By 6 months, all infants had titers below the protective threshold. In a multivariable analysis, infant age was the strongest predictor of susceptibility (odds ratio = 2.13 for each additional month increase; 95% confidence interval: 1.52-2.97).
CONCLUSIONS
Most infants were susceptible to measles by 3 months of age in this elimination setting. Our findings inform important policy discussions relating to the timing of the first dose of measles-containing vaccine and infant postexposure prophylaxis recommendations.

Identifiants

pubmed: 31753911
pii: peds.2019-0630
doi: 10.1542/peds.2019-0630
pii:
doi:

Substances chimiques

Antibodies, Neutralizing 0
Antibodies, Viral 0
Measles Vaccine 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2019 by the American Academy of Pediatrics.

Déclaration de conflit d'intérêts

POTENTIAL CONFLICT OF INTEREST: The authors have indicated they have no potential conflicts of interest to disclose.

Auteurs

Michelle Science (M)

Division of Infectious Diseases, Department of Paediatrics, and michelle.science@sickkids.ca.
Public Health Ontario, Toronto, Ontario, Canada.
Departments of Paediatrics and.

Rachel Savage (R)

Public Health Ontario, Toronto, Ontario, Canada.
Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.

Alberto Severini (A)

National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada.
Department of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada.

Elizabeth McLachlan (E)

National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada.

Stephanie L Hughes (SL)

Public Health Ontario, Toronto, Ontario, Canada.

Callum Arnold (C)

Division of Infectious Diseases, Department of Paediatrics, and.

Susan Richardson (S)

Division of Microbiology, Department of Paediatric Laboratory Medicine, The Hospital for Sick Children, Toronto, Ontario, Canada.

Natasha Crowcroft (N)

Public Health Ontario, Toronto, Ontario, Canada.
Laboratory Medicine and Pathobiology, University of Toronto, Toronto Canada.
Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
ICES, Toronto, Ontario, Canada.

Shelley Deeks (S)

Public Health Ontario, Toronto, Ontario, Canada.
Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.

Scott Halperin (S)

Canadian Center for Vaccinology (CCfV), IWK Health Centre, Nova Scotia Health Authority (NSHA), and Dalhousie University, Halifax, Nova Scotia (NS), Canada; and.

Kevin Brown (K)

Public Health Ontario, Toronto, Ontario, Canada.
Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
ICES, Toronto, Ontario, Canada.

Todd Hatchette (T)

Canadian Center for Vaccinology (CCfV), IWK Health Centre, Nova Scotia Health Authority (NSHA), and Dalhousie University, Halifax, Nova Scotia (NS), Canada; and.

Jonathan Gubbay (J)

Division of Infectious Diseases, Department of Paediatrics, and.
Public Health Ontario, Toronto, Ontario, Canada.
Departments of Paediatrics and.
Laboratory Medicine and Pathobiology, University of Toronto, Toronto Canada.

Tony Mazzulli (T)

Public Health Ontario, Toronto, Ontario, Canada.
Laboratory Medicine and Pathobiology, University of Toronto, Toronto Canada.
Mount Sinai Hospital, University Health Network, Toronto, Ontario, Canada.

Shelly Bolotin (S)

Public Health Ontario, Toronto, Ontario, Canada; michelle.science@sickkids.ca.
Laboratory Medicine and Pathobiology, University of Toronto, Toronto Canada.
Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH